Phaseline

Targets › USES

USES: drug programs, companies and trials

1 program from 1 company in 2 trials: 1 Phase 3, 1 Phase 2; Neurology, Other; next expected readout Mar 2027.

Open in Phaseline: the race on USES, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
UMC UtrechtEtidronate
Bisphosphonate; inhibits mineralization by suppressing osteoclast activity and reducing bo
USESPhase 3Pseudoxanthoma Elasticum; Fahr DiseaseMar 2027

Conditions

Pseudoxanthoma Elasticum (1) Fahr Disease (1)

Modalities

small molecule (1)

Companies

UMC Utrecht (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.